PA
VRTX icon

Perceptive Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Perceptive Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-100,000
Closed -$11.9M – 176
2014
Q4 		$11.9M Buy
+100,000
New +$11.3M 1% 31
2014
Q3 		– Sell
-30,000
Closed -$2.84M – 141
2014
Q2 		$2.84M Sell
30,000
-270,000
-90% -$18.9M 0.28% 57
2014
Q1 		$21.2M Buy
+300,000
New +$23.8M 2.23% 12

Other funds holding VRTX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Perceptive Advisors's VRTX Position: Q3 2018 in Review

Perceptive Advisors sold out of Vertex Pharmaceuticals (VRTX) in Q3 2018, closing a stake of 75,898 shares — an estimated $12.9M sold.

Perceptive Advisors first reported a position in VRTX in Q2 2013 and held it in 18 quarters. The position peaked at $60.3M in Q4 2013. 697 funds tracked by Wall St. Rank hold VRTX as of Q3 2018.

  • Perceptive Advisors reported no remaining Vertex Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
  • Perceptive Advisors sold 75,898 Vertex Pharmaceuticals shares in Q3 2018, an estimated $12.9M.
  • Perceptive Advisors first reported a position in Vertex Pharmaceuticals in Q2 2013 and held it in 18 quarters.
  • Perceptive Advisors's Vertex Pharmaceuticals position peaked at $60.3M in Q4 2013.
  • 697 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2018.

Based on Perceptive Advisors's 13F filing for Q3 2018, filed 14 Nov 2018.